Precision medicine for children with cancer
Precision Medicine for Every Child With Cancer
This study is testing if personalized medicine can improve treatment and outcomes for children with different types of cancer in Australia and New Zealand.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 3500 (estimated) |
| Ages | 0 Years to 25 Years |
| Sex | All |
| Sponsor | Australian & New Zealand Children's Haematology/Oncology Group Academic / other |
| Locations | 11 sites (Adelaide and 10 other locations) |
| Trial ID | NCT05504772 on ClinicalTrials.gov |
What this trial studies
This study aims to enhance outcomes for childhood cancer patients by implementing precision medicine approaches. It will utilize comprehensive molecular profiling and preclinical drug testing in real-time for high-risk patients, while also exploring the role of precision medicine in diagnosing and stratifying risk in non-high-risk childhood cancers. The study will extend the ZERO platform to all children with cancer in Australia and New Zealand, evaluating the benefits of precision medicine across various childhood cancer types and risk groups through integrative tumor-germline whole genome sequencing analysis.
Who should consider this trial
Good fit: Ideal candidates for this study are children under 18 years old diagnosed with any form of cancer.
Not a fit: Patients with a life expectancy of less than 6 weeks at the time of enrollment may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could lead to improved diagnosis and treatment strategies for children with various types of cancer.
How similar studies have performed: Previous studies have shown success in using precision medicine approaches for high-risk pediatric cancers, but this study aims to explore its application in non-high-risk cases, making it a novel endeavor.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age \< 18 years Note: Individual patients aged 19 - 25 years old with a pediatric cancer, e.g., neuroblastoma, may be enrolled after discussion with, and at the discretion of, the Study Chair or their delegate. 2. Life expectancy \>6 weeks at time of enrolment 3. Consent i. Signed and dated informed consent for study enrolment from participant aged ≥ 18 years or from parent/guardian of participant aged \<18 years. ii. Separate signed and dated informed consent for understanding the role of germline testing and choice for the return of germline results.
Where this trial is running
Adelaide and 10 other locations
- Women's and Children's Hospital — Adelaide, Australia (Recruiting)
- Queensland Children's Hospital — Brisbane, Australia (Recruiting)
- Royal Hobart Hospital — Hobart, Australia (Recruiting)
- Monash Children's Hospital — Melbourne, Australia (Recruiting)
- Royal Children's Hospital — Melbourne, Australia (Recruiting)
- John Hunter Children's Hospital — Newcastle, Australia (Recruiting)
- Perth Children's Hospital — Perth, Australia (Recruiting)
- Sydney Children's Hospital, Randwick — Sydney, Australia (Recruiting)
- The Children's Hospital at Westmead — Sydney, Australia (Recruiting)
- Starship Children's Hospital — Auckland, Grafton, New Zealand (Recruiting)
- Christchurch Hospital — Christchurch, New Zealand (Not_yet_recruiting)
Study contacts
- Principal investigator: David Ziegler — Schn
- Study coordinator: National Study Coordinator
- Email: SCHN-ZERO2@health.nsw.gov.au
- Phone: +61 2 9382 3102
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.